Press Releases
Merck’s KEYTRUDA Receives Two New Approvals in Japan
Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan...
Press Releases
Imfinzi approved in Japan for the treatment of extensive-stage small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide...
Clinical Trials
AstraZeneca Phase I clinical trial initiated for COVID-19 monoclonal antibody
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the...
Drug Research
AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
AbbVie and Harvard University announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS) to study and develop...
News
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Bristol Myers Squibb and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic...
Clinical Trials
BMS Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include...
Press Releases
Mitsubishi Tanabe Pharma Launch of VAFSEO,for the treatment of renal anemia in Japan
Mitsubishi Tanabe Pharma Corporation announced that MTPC is launchingVAFSEO®Tablets 150mg and 300mg (VAFSEO®, vadadustat) which is anoralhypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in-licensed from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
